Literature DB >> 3036638

In vitro interferon producing activity of peripheral mononuclear cells in patients with chronic liver disease.

K Matsushita, T Arima, H Nagashima.   

Abstract

Interferon-gamma (IFN-gamma) was induced from a human peripheral mononuclear fraction by incubation with a streptococcal preparation stabilized with penicillin G (OK432). This IFN-gamma-producing activity was significantly reduced in patients with chronic hepatitis and hepatocellular carcinoma. In patients with liver cirrhosis it was also reduced but not significantly. Serum hepatitis B virus DNA and skin tests for the purified protein derivative of tuberculin, phytohemagglutinin-P and a polysaccharide fraction prepared from streptococcus pyogenes Su strain were determined to have no significant relation to this IFN-gamma-producing activity. Although the addition of interleukin 2 (IL-2) to the culture medium enhanced the IFN-gamma-producing activity, there was no difference in this enhancement between normal control and chronic hepatitis. Therefore reduction of the IFN-gamma-producing activity observed in chronic hepatitis seems to be caused by a decreased number of IFN-gamma-producing activity cells or hypofunction of these cells or both. Since HBeAg became negative in patients whose IFN-gamma-producing activity was increased by the administration of the immunopotentiator OK432 or IFN-beta, the IFN-producing system in the patients with B type hepatitis may contribute to the elimination of HBV. Adenine arabinoside suppressed IFN-gamma-producing activity both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036638     DOI: 10.1007/BF02774213

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  21 in total

1.  Cellular immunity and hepatitis-associated, Australia antigen liver disease.

Authors:  F J Dudley; R A Fox; S Sherlock
Journal:  Lancet       Date:  1972-04-01       Impact factor: 79.321

2.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

3.  Failure to demonstrate circulating interferon during incubation period and acute stage of transfusion-associated hepatitis.

Authors:  D A Hill; J H Walsh; R H Purcell
Journal:  Proc Soc Exp Biol Med       Date:  1971-03

4.  Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon.

Authors:  J M Zarling; L Eskra; E C Borden; J Horoszewicz; W A Carter
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  Immunoregulation by gamma-interferon?

Authors:  T Basham; T C Merigan
Journal:  Nature       Date:  1982-10-28       Impact factor: 49.962

7.  Enhanced humoral antibody production in mice against influenza virus by streptococcal preparation OK-432.

Authors:  T Watanabe; K Adachi; Y Horikawa; K Sato; H Saito
Journal:  Microbiol Immunol       Date:  1981       Impact factor: 1.955

8.  gamma-Interferon induced by S. aureus protein A augments natural killing and ADCC.

Authors:  W J Catalona; T L Ratliff; R E McCool
Journal:  Nature       Date:  1981-05-07       Impact factor: 49.962

9.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

Authors:  G H Scullard; R B Pollard; J L Smith; S L Sacks; P B Gregory; W S Robinson; T C Merigan
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

10.  Lack of correlation between interferon production of mononuclear cells and virus replication in chronic hepatitis B virus infection.

Authors:  R Kinoshita; K Miura; S Suzuki; H Uchino
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.